Short interest for Seres Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Seres Therapeutics's stock. Short interest data is updated every two weeks.

Seres Therapeutics Stock (NASDAQ:MCRB), Short Interest Report

Seres Therapeutics

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

xr:d:DAFih-sWqhI:2,j:46865321670,t:23051015

News

Intraday Update

Markets

Movers

AFIB

AFRM

ALAB

AMRC

AMRK

AOSL

APEI

ARKO

BROS

CLOV

CPNG

CRCT

CRUS

DTCK

ELAN

FLYW

GMED

Hannon Armstrong Sustainable Infrastructure Capital

HASI

INOD

INSP

ISUN

LAZR

LYFT

MASI

MCRB

MXCT

MYGN

NIVF

PWSC

QLYS

REBN

RPTX

SATS

SHLS

SHOP

SIGA

SMLR

STAA

SWIM

TEVA

TIVC

TMCI

TOST

TRIP

TWLO

UBER

UPST

VECO

VLCN

Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Uber

Earnings

Eurozone

Commodities

Trading Ideas

Nasdaq Down Over 50 Points; Uber Posts Q1 Loss

Penny Stocks

Price Target

Small Cap

Pre-Market Outlook

Analyst Ratings

CHPT

COOK

CRWD

ROST

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Emerson Electric To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Wednesday

Seres Therapeutics Inc

Oppenheimer analyst Jeff Jones maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Outperform and lowers the price target from $5 to $4.

Oppenheimer Maintains Outperform on Seres Therapeutics, Lowers Price Target to $4

<h3>Gainers</h3>
<ul>
<li>Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) shares increased by 37.7% to $14.14 during Thursday's regular session. The company's market cap stands at $814.1 million. As per the press release, Q2 earnings came out today. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) shares moved upwards by 36.28% to $1.02. The market value of their outstanding shares is at $154.2 million. The company's, Q1 earnings came out yesterday. </li>
<li>G1 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTHX#NASDAQ">GTHX</a>) shares rose 35.08% to $5.79. The company's market cap stands at $302.9 million. </li>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) shares rose 31.75% to $7.51. The market value of their outstanding shares is at $11.8 million. </li>
<li>Zai Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) stock increased by 25.28% to $20.76. The company's market cap stands at $2.0 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) shares moved upwards by 24.07% to $1.34. The market value of their outstanding shares is at $21.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock decreased by 58.7% to $0.55 during Thursday's regular session. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock fell 41.89% to $2.44. The company's market cap stands at $165.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) stock fell 41.11% to $4.7. The market value of their outstanding shares is at $163.5 million. As per the news, the Q1 earnings report came out today. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock fell 35.56% to $1.38. The market value of their outstanding shares is at $9.1 million. As per the press release, Q1 earnings came out today. </li>
<li>NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) stock decreased by 31.51% to $8.63. The market value of their outstanding shares is at $247.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) stock decreased by 22.35% to $2.19. The market value of their outstanding shares is at $61.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CCLD

CTMX

EMBC

GTHX

NPCE

RAPT

RVPH

SYRA

VCNX

ZLAB

12 Health Care Stocks Moving In Thursday's Intraday Session

Shares of Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) fell sharply during Wednesday's session after the company reported first-quarter financial results and issued second-quarter revenue <a href="https://www.benzinga.com/news/earnings/24/05/38682848/upstart-q1-earnings-revenue-beat-eps-beat-targeting-positive-ebitda-in-2024-and-more">guidance below estimates</a>.
Upstart reported first-quarter revenue of $128 million, which beat the consensus estimate of $124.867 million, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Upstart expects second-quarter revenue of approximately $125 million versus estimates of $140.83 million. The company anticipates a second-quarter adjusted EBITDA loss of approximately $25 million.
Upstart shares dipped 10.3% to $21.96 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Reborn Coffee, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REBN#NASDAQ">REBN</a>) shares jumped 132.9% to $4.0297 after the company announced a significant expansion into the China market through a strategic Master License Agreement with IAID Co.</li>
<li>iSun, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISUN#NASDAQ">ISUN</a>) gained 49% to $0.1966.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) jumped 36.4% to $1.48.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) rose 34% to $1.4099.</li>
<li>Innodata Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) shares gained 31.5% to $8.86 after the company reported a year-over-year increase in first-quarter financial results.</li>
<li>Cricut, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) gained 31% to $7.25 after the company reported better-than-expected first-quarter GAAP EPS results.</li>
<li>MaxCyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>) rose 27.6% to $5.01 following upbeat quarterly results.</li>
<li>Ameresco, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NASDAQ">AMRC</a>) gained 27.6% to $28.47 following strong quarterly results.</li>
<li>Davis Commodities Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTCK#NASDAQ">DTCK</a>) rose 26.8% to $1.5580</li>
<li>Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) surged 26.5% to $17.11 following strong quarterly earnings.</li>
<li>American Public Education, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) rose 23.3% to $18.71 following upbeat quarterly results.</li>
<li>Globus Medical, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) gained 23.3% to $63.35 after the company reported better-than-expected first-quarter financial results and raised its FY24 guidance.</li>
<li>Kyndryl Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) jumped 21.6% to $25.25 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>PowerSchool Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWSC#NYSE">PWSC</a>) gained 21.2% to $20.17 following a report suggesting Bain is pursuing a takeover of the company.</li>
<li>Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) rose 21.1% to $24.02 following better-than-expected first-quarter earnings.</li>
<li>Arko Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKO#NYSE">ARKO</a>) gained 20.3% to $5.15 following first-quarter earnings.</li>
<li>Latham Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) gained 19% to $3.5609 following strong first-quarter earnings.</li>
<li>Hyster-Yale Materials Handling, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) surged 18.2% to $69.74 following UPBEAT first-quarter earnings.</li>
<li>Alpha and Omega Semiconductor Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOSL#NASDAQ">AOSL</a>) jumped 17.7% to $26.22 after reporting strong quarterly results.</li>
<li>Neo-Concept International Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) gained 17.2% to $1.1529 after declining over 6% on Tuesday.</li>
<li>Oddity Tech Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) gained 15.8% to $36.19 after the company reported better-than-expected first-quarter financial results and issued FY24 EPS guidance above estimates.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) climbed 15.5% to $32.82 after the company reported better-than-expected first-quarter financial results and raised its FY24 revenue guidance.</li>
<li>Louisiana-Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>) gained 15% to $83.93 following better-than-expected first-quarter financial results.</li>
<li>RingCentral, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) rose 14.8% to $34.42 after the company reported better-than-expected first-quarter financial results and raised its FY24 guidance.</li>
<li>Luminar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) rose 14.5% to $1.89 as the company posted a narrower-than-expected quarterly loss.</li>
<li>Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) gained 14.2% to $27.09 after the company reported better-than-expected quarterly sales results.</li>
<li>Hannon Armstrong Sustainable Infrastructure Capital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HASI#NASDAQ">HASI</a>) gained 13.9% to $29.84 following upbeat earnings.</li>
<li>Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) rose 13% to $15.75 after the company reported mixed first quarter financial results.</li>
<li>Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) gained 11.7% to $3.6650 after the company posted better-than-expected results for its first quarter.</li>
<li>Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) gained 10.1% to $90.01 after the company reported first quarter financial results.</li>
<li>Cirrus Logic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) jumped 9.6% to $99.93 as the company posted better-than-expected results for its fourth quarter.</li>
<li>Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares gained 9.5% to $0.81 after the company reported better than expected first-quarter financial results.</li>
<li>Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) gained 8.8% to $18.08 following better-than-expected first-quarter results.</li>
<li>Veeco Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VECO#NASDAQ">VECO</a>) rose 6.9% to $40.08 following upbeat results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Treace Medical Concepts, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) shares dipped 60.8% to $4.3650 after the company reported first-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>DoubleVerify Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) fell 38.5% to $18.79 after the company reported first-quarter financial results.</li>
<li>Inspire Medical Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) fell 34.3% to $161.35 following first-quarter results.</li>
<li>Definitive Healthcare Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) dipped 32.2% to $4.9150 after the company reported worse-than-expected first-quarter sales results.</li>
<li>Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) fell 31.1% to $0.7653 following quarterly results.</li>
<li>Tripadvisor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) fell 28.4% to $18.24 after Liberty Tripadvisor and the Special Committee ceased discussions with third parties with respect to a potential transaction.</li>
<li>ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) shares fell 25.2% to $11.98 after the company reported first-quarter financial results and issued second-quarter guidance below estimates.</li>
<li>LegalZoom.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>) dipped 23.3% to $9.35 after the company reported worse-than-expected first-quarter financial results and issued second-quarter revenue guidance below estimates.</li>
<li>Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) fell 22.7% to $21.78 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Grocery Outlet Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) dipped 22.2% to $20.17 after the company reported worse-than-expected first-quarter adjusted EPS results.</li>
<li>Flywire Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) shares declined 21.7% to $16.08 after the company reported worse-than-expected first-quarter EPS results and issued second-quarter revenue guidance below estimates.</li>
<li>SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) dipped 20.6% to $8.31 following first-quarter results.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) fell 19.8% to $61.76 following first-quarter earnings..</li>
<li>Rapid7, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) dipped 18.6% to $37.26 following first-quarter earnings..</li>
<li>Acutus Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFIB#NASDAQ">AFIB</a>) fell 17.1% to $0.1020 after jumping 15% on Tuesday. Nasdaq, last week, notified the company that it has not regained compliance with listing rule 5550(a)(2).</li>
<li>Shoals Technologies Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) shares fell 14.1% to $7.56 after the company reported worse-than-expected first-quarter sales results.</li>
<li>Masimo Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) fell 13.8% to $117.23 following first-quarter earnings. The company&#8217;s second-quarter guidance midpoint was below consensus estimates.</li>
<li>EchoStar Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) dipped 13.6% to $14.99 following worse-than-expected first-quarter financial results.</li>
<li>STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) dipped 11.8% to $41.10 following quarterly results.</li>
<li>Volcon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) shares declined 11.8% to $0.26 after the company reported a year-over-year decrease in first-quarter sales results.</li>
<li>Qualys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) fell 10.1% to $149.21 after the company reported first-quarter earnings and issued second-quarter revenue guidance below estimates.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) fell 9.1% to $31.74 following third-quarter earnings.</li>
<li>Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) dipped 8.6% to $64.40. Uber posted weaker-than-expected fiscal first-quarter financial results.</li>
<li>Coupang, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) fell 7.8% to $21.78 after the company reported mixed first-quarter financial results.</li>
<li>Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) shares declined 6.3% to $71.37 following first-quarter results.</li>
<li>Centrus Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>) shares declined 6.2% to $41.56 following first-quarter results.</li>
<li>A-Mark Precious Metals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRK#NASDAQ">AMRK</a>) shares fell 5.5% to $38.14 following fiscal third quarter 2024 results.</li>
<li>Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) shares fell 5.5% to $59.86 following first-quarter results.</li>
<li>OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) shares fell 5.4% to $1.23 after the company reported worse-than-expected first-quarter financial results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38702433/airbnb-gears-up-for-q1-print-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Airbnb Gears Up For Q1 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>

Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

WIIM

Seres Therapeutics shares are trading lower after the company reported Q1 financial results.

<h3>Gainers</h3>
<ul>
<li>MaxCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>) shares rose 26.5% to $4.97 during Wednesday's regular session. The company's market cap stands at $519.4 million. The company's, Q1 earnings came out yesterday. </li>
<li>Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) stock moved upwards by 25.25% to $16.93. The market value of their outstanding shares is at $8.3 billion. The company's, Q1 earnings came out today. </li>
<li>Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) shares rose 22.17% to $62.75. The company's market cap stands at $8.4 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) stock moved upwards by 20.63% to $0.89. The company's market cap stands at $442.6 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) stock moved upwards by 17.86% to $3.76. The company's market cap stands at $141.3 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock rose 17.35% to $1.76. The company's market cap stands at $11.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) shares fell 62.3% to $4.19 during Wednesday's regular session. The company's market cap stands at $259.5 million. The company's, Q1 earnings came out yesterday. </li>
<li>Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) shares decreased by 34.69% to $160.44. The market value of their outstanding shares is at $4.8 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Definitive Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) shares declined by 31.52% to $4.96. The company's market cap stands at $584.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock declined by 30.64% to $0.77. The company's market cap stands at $116.2 million. As per the news, the Q1 earnings report came out today. </li>
<li>SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) shares fell 22.47% to $8.11. The market value of their outstanding shares is at $576.7 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock fell 21.25% to $22.17. The market value of their outstanding shares is at $155.8 million. The company's, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VIGL

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 50 points on Wednesday.
Following the market opening Wednesday, the Dow traded down 0.05% to 38,863.85 while the NASDAQ fell 0.37% to 16,272.05. The S&amp;P 500 also fell, dropping, 0.17% to 5,179.08.
Check This Out: <a href="https://www.benzinga.com/news/24/05/38699603/top-2-financial-stocks-that-may-fall-off-a-cliff-in-may&quot;">Top 2 Financial Stocks That May Fall Off A Cliff In May </a>
Leading and Lagging Sectors Utilities shares rose by 0.2% on Wednesday.
In trading on Wednesday, real estate shares fell by 0.9%.
Top Headline
Uber Technologies, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) posted weaker-than-expected fiscal first-quarter financial results.
Uber reported fiscal first-quarter 2024 revenue growth of 15% year-on-year to $10.10 billion, marginally missing the analyst consensus estimate of $10.11 billion. Uber&#8217;s GAAP EPS of 32 cents loss missed the analyst consensus estimate of 23 cents.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Reborn Coffee, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REBN#NASDAQ">REBN</a>) shares shot up 104% to $3.53 after the company announced a significant expansion into the China market through a strategic Master License Agreement with IAID Co.
Shares of iSun, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISUN#NASDAQ">ISUN</a>) got a boost, surging 44% to $0.1904.
Innodata Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) shares were also up, gaining 39% to $9.35 after the company reported a year-over-year increase in first-quarter financial results.
Equities Trading DOWN
Treace Medical Concepts, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) shares dropped 60% to $4.46 after the company reported first-quarter financial results and issued FY24 revenue guidance below estimates.
Shares of DoubleVerify Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) were down 40% to $18.46 after the company reported first-quarter financial results.
Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) was down, falling 35% to $0.7181 following quarterly results.
Also Check This Out: <a href="https://www.benzinga.com/news/earnings/24/05/38699968/how-to-earn-500-a-month-from-maximus-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Maximus Stock Ahead Of Q2 Earnings</a> 
Commodities In commodity news, oil traded down 0.9% to $77.69 while gold traded down 0.2% at $2,319.80.
Silver traded down 0.1% to $27.505 on Wednesday, while copper fell 1.3% to $4.5395.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.2%, Germany's DAX rose 0.1% and France's CAC 40 gained 0.7%. Spain's IBEX 35 Index rose 0.4%, while London's FTSE 100 rose 0.3%.
Spain&#8217;s industrial output declined by 1.2% year-over-year in March compared to a revised 1.3% gain in the previous month. German industrial production fell by 0.4% month-over-month in March versus a revised 1.7% increase in the earlier month.
Asia Pacific Markets
Asian markets closed lower on Wednesday, with Japan's Nikkei falling 1.63%, China's Composite Index declining 0.61%, Hong Kong's Hang Seng Index dipping 0.90% and India's S&amp;P BSE Sensex falling 0.1%.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Economics
Mortgage applications in the US increased by 2.6% from the prior week in the period ending May 3.
Now Read This: <a href="https://www.benzinga.com/news/24/05/38699733/datadog-to-rally-around-25-here-are-10-top-analyst-forecasts-for-wednesday">Datadog To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Wednesday</a>

Biotech

Guidance

Health Care

General

Seres Therapeutics' Q1 Cash And Cash Equivalents Of $111.2M Is Expected To Provide Cash Runway Into Q4 Of 2024

Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.34) by 20.59 percent. This is a 52.63 percent increase over losses of $(0.57) per share from the same period last year.

Earnings Beats

Seres Therapeutics Q1 2024 GAAP EPS $(0.27) Beats $(0.34) Estimate

Seres Therapeutics Concludes Enrollment In Cohort 2 Of Phase 1B Trial Of SER-155 In Allogeneic Hematopoietic Stem Cell Transplant Patients; Clinical Data Readout Expected End Of Q3 2024

Seres Therapeutics Announced That On March 25, 2024, The Compensation And Talent Committee Of Seres' Board Of Directors Granted Inducement Equity Grants Of 700,000 Shares To Marella Thorell, New Executive Vice President And CFO

Oppenheimer analyst Jeff Jones maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Outperform and lowers the price target from $9 to $5.

Oppenheimer Maintains Outperform on Seres Therapeutics, Lowers Price Target to $5

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Morgan Stanley boosted the price target for Sea Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/se#NYSE">SE</a>) from $47 to $65. Morgan Stanley analyst Mark Goodridge maintained an Equal-Weight rating. Sea shares gained 3.4% to close at $55.75 on Tuesday. <a href="https://www.benzinga.com/quote/SE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays raised the price target for Target Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgt#NYSE">TGT</a>) from $142 to $169. Barclays analyst Seth Sigman maintained an Equal-Weight rating. Target shares jumped 12% to close at $168.58 on Tuesday. <a href="https://www.benzinga.com/quote/TGT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Chardan Capital lowered Seres Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mcrb#NASDAQ">MCRB</a>) price target from $10 to $8. Chardan Capital analyst Keay Nakae maintained a Buy rating. Seres Therapeutics shares fell 7% to close at $1.06 on Tuesday. <a href="https://www.benzinga.com/quote/MCRB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities boosted the price target for Nordstrom, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jwn#NYSE">JWN</a>) from $13 to $15. B of A Securities analyst Lorraine Hutchinson maintained an Underperform rating. Nordstrom shares gained 1.6% to close at $20.90 on Tuesday. <a href="https://www.benzinga.com/quote/JWN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut ChargePoint Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chpt#NYSE">CHPT</a>) price target from $4 to $3. Needham analyst Chris Pierce maintained a Buy rating. ChargePoint shares fell 3.4% to close at $2.00 on Monday. <a href="https://www.benzinga.com/quote/CHPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc boosted the price target for CrowdStrike Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crwd#NASDAQ">CRWD</a>) from $375 to $430. Keybanc analyst Eric Heath maintained an Overweight rating. CrowdStrike shares fell 5.2% to close at $297.56 on Tuesday. <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo slashed Twilio Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/twlo#NYSE">TWLO</a>) price target from $70 to $60. Wells Fargo analyst Michael Turrin maintained an Equal-Weight rating. Twilio shares fell 5.9% to close at $56.66 on Tuesday. <a href="https://www.benzinga.com/quote/TWLO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Guggenheim boosted Ross Stores, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rost#NASDAQ">ROST</a>) price target from $140 to $165. Guggenheim analyst Robert Drbul maintained a Buy rating. Ross Stores shares fell 0.5% to close at $149.17 on Tuesday. <a href="https://www.benzinga.com/quote/ROST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity cut Traeger, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cook#NYSE">COOK</a>) price target from $5 to $4. Canaccord Genuity analyst Brian McNamara maintained a Buy rating. Traeger shares fell 4.2% to close at $2.06 on Tuesday. <a href="https://www.benzinga.com/quote/COOK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Berenberg raised Emerson Electric Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/emr#NYSE">EMR</a>) price target from $100 to $130. Berenberg analyst Philip Buller maintained a Buy rating. Emerson Electric shares fell 0.5% to close at $109.02 on Tuesday. <a href="https://www.benzinga.com/quote/EMR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/24/03/37505931/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q1"> Top 2 Utilities Stocks That May Fall Off A Cliff In Q1 </a>

Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Buy and lowers the price target from $10 to $8.

Chardan Capital Maintains Buy on Seres Therapeutics, Lowers Price Target to $8

Seres' $128M In Cash Balance, Planned Savings From Restructuring Announced In November 2023, And, Assuming Continued Revenue Growth Of Vowst, Expected Receipt Of The $45M Tranche B Under Its Secured Debt Will Support Its Operations Into Q4 2024

Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) reported quarterly losses of $(0.89) per share which beat the analyst consensus estimate of $(0.96) by 7.29 percent. This is a 61.47 percent increase over losses of $(2.31) per share from the same period last year. The company reported quarterly sales of $126.33 million which beat the analyst consensus estimate of $126.07 million by 0.21 percent. This is a 1.67K percent increase over sales of $7.13 million the same period last year.

Seres Therapeutics FY GAAP EPS $(0.89) Beats $(0.96) Estimate, Sales $126.33M Beat $126.07M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.
&bull; Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) is estimated to report quarterly earnings at $2.22 per share on revenue of $29.33 billion.
&bull; 2seventy bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>) is expected to report quarterly loss at $0.99 per share on revenue of $14.71 million.
&bull; CLPS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPS#NASDAQ">CLPS</a>) is expected to report earnings for its first quarter.
&bull; Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) is projected to report quarterly loss at $0.50 per share on revenue of $350 thousand.
&bull; Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $183.67 million.
&bull; Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) is projected to report quarterly loss at $1.39 per share on revenue of $2.55 million.
&bull; Consolidated Comms Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSL#NASDAQ">CNSL</a>) is likely to report quarterly loss at $0.36 per share on revenue of $276.94 million.
&bull; CECO Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) is likely to report quarterly earnings at $0.24 per share on revenue of $146.61 million.
&bull; 908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) is expected to report quarterly loss at $0.26 per share on revenue of $14.16 million.
&bull; Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) is projected to report quarterly loss at $0.26 per share on revenue of $19.85 million.
&bull; Broadwind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWEN#NASDAQ">BWEN</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $50.15 million.
&bull; Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) is projected to report quarterly loss at $0.03 per share on revenue of $541.17 million.
&bull; Riskified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $84.02 million.
&bull; Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $9.00 million.
&bull; L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $129.35 million.
&bull; Rand Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAND#NASDAQ">RAND</a>) is expected to report earnings for its fourth quarter.
&bull; Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) is likely to report earnings for its fourth quarter.
&bull; Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) is projected to report quarterly loss at $0.26 per share on revenue of $17.33 million.
&bull; First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $237.53 million.
&bull; Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $20.00 million.
&bull; SmartRent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) is likely to report quarterly loss at $0.01 per share on revenue of $59.49 million.
&bull; Ferguson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) is estimated to report quarterly earnings at $1.85 per share on revenue of $6.77 billion.
&bull; Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $41.78 million.
&bull; Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) is likely to report quarterly loss at $0.10 per share on revenue of $41.65 million.
&bull; V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $1.01 billion.
&bull; Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) is likely to report earnings for its fourth quarter.
&bull; Myers Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $196.19 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is estimated to report quarterly earnings at $0.80 per share on revenue of $197.70 million.
&bull; Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is estimated to report quarterly earnings at $0.88 per share on revenue of $4.39 billion.
&bull; BlackRock Cap Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKCC#NASDAQ">BKCC</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $20.32 million.
&bull; Presto Automation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRST#NASDAQ">PRST</a>) is likely to report earnings for its fourth quarter.
&bull; Kingsway Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFS#NYSE">KFS</a>) is likely to report earnings for its fourth quarter.
&bull; Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) is expected to report quarterly loss at $0.19 per share on revenue of $293.53 million.
&bull; Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) is likely to report earnings for its fourth quarter.
&bull; TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) is likely to report quarterly loss at $0.08 per share on revenue of $1.00 million.
&bull; Entravision Comms (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVC#NYSE">EVC</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $308.47 million.
&bull; Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) is projected to report quarterly loss at $0.87 per share on revenue of $10.58 million.
&bull; Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) is likely to report quarterly loss at $3.66 per share on revenue of $73.50 million.
&bull; Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) is expected to report quarterly loss at $0.62 per share on revenue of $8.01 million.
&bull; Allient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNT#NASDAQ">ALNT</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $132.56 million.
&bull; Bristow Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTOL#NYSE">VTOL</a>) is projected to report quarterly earnings at $0.54 per share on revenue of $329.20 million.
&bull; Greenlight Capital Re (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLRE#NASDAQ">GLRE</a>) is estimated to report earnings for its fourth quarter.
&bull; Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $34.10 million.
&bull; Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) is projected to report quarterly loss at $1.07 per share on revenue of $1.06 million.
&bull; Socket Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCKT#NASDAQ">SCKT</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $4.91 million.
&bull; Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) is expected to report quarterly loss at $0.40 per share on revenue of $1.95 million.
&bull; Park-Ohio Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PKOH#NASDAQ">PKOH</a>) is likely to report quarterly earnings at $0.55 per share on revenue of $386.45 million.
&bull; W&amp;T Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $138.42 million.
&bull; Cadre Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDRE#NYSE">CDRE</a>) is projected to report quarterly earnings at $0.18 per share on revenue of $121.79 million.
&bull; Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $14.50 million.
&bull; Agiliti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGTI#NYSE">AGTI</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $291.41 million.
&bull; Nuvei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEI#NASDAQ">NVEI</a>) is projected to report quarterly earnings at $0.45 per share on revenue of $319.51 million.
&bull; Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) is estimated to report quarterly earnings at $0.84 per share on revenue of $283.00 million.
&bull; Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $152.30 million.
&bull; Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) is likely to report quarterly loss at $0.08 per share on revenue of $11.63 million.
&bull; Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) is expected to report earnings for its fourth quarter.
&bull; MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $74.86 million.
&bull; Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) is likely to report earnings for its fourth quarter.
&bull; Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) is expected to report quarterly loss at $0.02 per share on revenue of $49.27 million.
&bull; American Public Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $150.47 million.
&bull; Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $249.68 million.
&bull; Crexendo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $13.80 million.
&bull; Aeva Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NYSE">AEVA</a>) is likely to report quarterly loss at $0.15 per share on revenue of $1.57 million.
&bull; LSB Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXU#NYSE">LXU</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $127.21 million.
&bull; PlayAGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGS#NYSE">AGS</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $92.57 million.
&bull; Full House Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLL#NASDAQ">FLL</a>) is likely to report quarterly loss at $0.14 per share on revenue of $63.13 million.
&bull; CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is expected to report quarterly earnings at $0.82 per share on revenue of $839.04 million.
&bull; HashiCorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCP#NASDAQ">HCP</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $149.29 million.
&bull; Banco BBVA Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAR#NYSE">BBAR</a>) is estimated to report earnings for its fourth quarter.
&bull; NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) is expected to report quarterly loss at $0.31 per share on revenue of $17.46 million.
&bull; Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) is projected to report earnings for its fourth quarter.
&bull; Ooma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $61.46 million.
&bull; ChargePoint Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) is likely to report quarterly loss at $0.13 per share on revenue of $119.59 million.
&bull; ODDITY Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) is expected to report earnings for its fourth quarter.
&bull; NewtekOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEWT#NASDAQ">NEWT</a>) is projected to report quarterly earnings at $0.58 per share on revenue of $63.35 million.
&bull; Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) is expected to report quarterly earnings at $0.38 per share on revenue of $262.95 million.
&bull; Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) is projected to report earnings for its fourth quarter.
&bull; Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) is likely to report earnings for its fourth quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AEVA

AGTI

ALNT

AOMR

AQST

AXGN

BASE

BBAR

BKCC

BNGO

BWEN

CDRE

CECO

CERS

CGEN

CIFR

CLPS

CNSL

CPIX

CXDO

DAVE

FERG

FSTR

FWRG

GBTG

GLRE

ISPO

MASS

MLNK

MRNS

NEWT

NUWE

NVEI

NYXH

OFIX

OOMA

PKOH

PRST

PSTV

RAND

RIGL

RSKD

SCKT

SEAT

SMRT

SOPH

STIM

TCON

TSVT

VTOL

WEYS

Earnings Scheduled For March 5, 2024

Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-03-05. Here's what investors need to know before the announcement.
Analysts estimate that Seres Therapeutics will report an earnings per share (EPS) of $-0.50. 
Seres Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.13, which was followed by a 39.43% increase in the share price the next day.
Here's a look at Seres Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.50</td>
<td>0.55</td>
<td>-0.55</td>
<td>-0.46</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.37</td>
<td>0.36</td>
<td>-0.57</td>
<td>-0.54</td>
</tr>
<tr>
<td>Price Change %</td>
<td>39.0%</td>
<td>-6.0%</td>
<td>-5.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709568159_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Seres Therapeutics were trading at $1.23 as of March 01. Over the last 52-week period, shares are down 78.52%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/MCRB/earnings">To track all earnings releases for Seres Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Seres Therapeutics's Earnings: A Preview

Management

Seres Therapeutics Announced That Marella Thorell Will Join As Executive Vice President And Chief Financial Officer, As Of March 25, Following David Arkowitz's Retirement

Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) (&quot;Seres&quot; or the &quot;Company&quot;), a leading microbiome therapeutics company, today announced that on January 10, 2024, the Compensation and Talent Committee of Seres&#39; board of directors granted inducement equity grants covering an aggregate of 67,500 shares of its common stock to one new employee, consisting of stock options to purchase 45,000 shares of common stock and restricted stock units (&quot;RSUs&quot;) covering 22,500 shares of its common stock.

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oppenheimer analyst Jeff Jones maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Outperform and lowers the price target from $10 to $9.

Oppenheimer Maintains Outperform on Seres Therapeutics, Lowers Price Target to $9

Seres Therapeutics Q1 2024 Earnings Preview

Seres Therapeutics GAAP EPS of -$0.27 beats by $0.07

Tivic Health Systems, NewGenIvf Group, Elanco Animal Health among healthcare movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Seres Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/mcrb-stock-quote/">MCRB</a>) just reported results for the first quarter of 2024.<ul><li>Seres Therapeutics reported earnings per share of -27 cents. This was above the analyst estimate for EPS of -34 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/mcrb-stock-earnings-seres-therapeutics-for-q1-of-2024/">MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q1 2024

ISUN, DTCK and MXCT among mid-day movers

Seres Therapeutics Inc. (MCRB) has disclosed a new risk, in the Share Price & Shareholder Rights category. Seres Therapeutics Inc. faces a signific...

Seres Therapeutics at Risk of Nasdaq Delisting: A Race Against Time to Bolster Stock Value

Canaccord Genuity analyst John Newman has maintained their bullish stance on MCRB stock, giving a Buy rating today. John Newman has given his Buy r...

Buy Rating Affirmed for Seres Therapeutics Amidst Strong Sales Trajectory and Promising Pipeline

In a report released today, Jeff Jones from Oppenheimer maintained a Buy rating on Seres Therapeutics (MCRB – Research Report), with a price target...

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Seres Therapeutics Stock (NASDAQ:MCRB), Short Interest Report

People Also Watch